Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Randomized, Double-Blind, Vehicle-Controlled Study to Assess the Safety, Tolerability, and Systemic Exposure of Cerdulatinib Gel, 0.37% in Adults With Vitiligo

NCT04103060 is registered in ClinicalTrials.gov with Dermavant Sciences GmbH as lead sponsor.

NCT NCT04103060
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04103060 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Randomized, Double-Blind, Vehicle-Controlled Study to Assess the Safety, Tolerability, and Systemic Exposure of Cerdulatinib Gel, 0.37% in Adults With Vitiligo
Lead sponsor
Dermavant Sciences GmbH
Phase
Phase 2
Overall status
Completed
Start date
September 27, 2019
Completion date
November 3, 2020
Enrollment
33 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

vitiligo